Increased Uptake of Currently-Available Therapies Will Drive Modest $400 Million Growth in the Parkinson's Disease Drug Market f

Generic Erosion of Key Agents Such as Pramipexole and Ropinirole Will Constrain the Overall Market, According to Findings from Decision Resources

BURLINGTON, Mass., Sept. 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, although increased uptake of currently-available therapies will drive modest $400 million growth in the Parkinson's disease drug market through 2019, generic erosion of key agents will constrain overall market growth in the United States, France, Germany, Italy, Spain, United Kingdom and Japan.

The Pharmacor 2010 findings from the topic entitled Parkinson's Disease reveal that the majority of sales will continue to be fueled by the leading dopamine agonists, driving the market from $2.6 billion in 2009 to $3 billion in 2019. The leading agents in this class include pramipexole (Boehringer Ingelheim's Mirapex/Mirapexin/Sifrol/BI-Sifrol, generics; Mirapex ER/Mirapexin ER/Sifrol Retard) and ropinirole (GlaxoSmithKline's Requip, generics; GlaxoSmithKline/SkyePharma's Requip XL/LP/RP/Modutab/Prolib).

Another key driver of growth in the Parkinson's disease drug market will be the increased uptake of Teva Pharmaceuticals/Lundbeck's Azilect/Agilect (rasagiline) in the United States and Europe through 2019 and the launch of this agent in Japan in 2015. Increased use of Azilect/Agilect, a monoamine oxidase B inhibitor, will be driven by clinical data supporting its use in early Parkinson's disease as a disease-modifying agent.

However, overall market growth will be constrained by the increased uptake of generic versions of immediate- and extended-release formulations of pramipexole as well as immediate- and controlled-release formulations of ropinirole. Additionally, Agilect/Azilect and Novartis/Orion Pharma's Comtan/Comtess/Stalevo (entacapone) will also lose patent exclusivity over the next decade.  

"By 2019, the genericization of several key Parkinson's disease therapies will create a fragmented market with no clear leader, as a large number of similarly priced drugs compete for the same patient share," said Decision Resources Analyst Sami Fam, Ph.D. "Future therapies in this indication will need to clearly differentiate themselves from other therapies to gain a competitive edge in this mature market."

About Pharmacor 2010

The newly redesigned Pharmacor advisory service offers clients in the biopharmaceutical industry the most up-to-date information available on commercially significant disease topics.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

Decision Resources, Inc.

Christopher Comfort


[email protected]

SOURCE Decision Resources